ACON vs XTNT vs GKOS vs NVCR vs ZBH

For growth investors, Aclarion, Inc.

(ACON) is the stronger pick with 999999% revenue growth year-over-year, versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 2x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -100. 0% for Aclarion, Inc. (ACON). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus ACON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zimmer Biomet Holdings, Inc.

(ZBH) is the lower-risk stock at 0. 60β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 260% more volatile than ZBH relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aclarion, Inc.

(ACON) is pulling ahead at 999999% versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). On earnings-per-share growth, the picture is similar: Aclarion, Inc. grew EPS 99. 8% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, ACON leads at 106. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zimmer Biomet Holdings, Inc.

(ZBH) is the more profitable company, earning 8. 6% net margin versus -95. 5% for Aclarion, Inc. — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZBH leads at 16. 5% versus -93. 1% for ACON. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 87.

3% to $33. 50.

In this comparison, ACON (100.

0% yield), ZBH (1. 2% yield) pay a dividend. XTNT, GKOS, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zimmer Biomet Holdings, Inc.

(ZBH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 1. 2% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZBH: -18. 8%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACON is a small-cap high-growth stock; XTNT is a small-cap high-growth stock; GKOS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; ZBH is a mid-cap quality compounder stock. ACON, ZBH pay a dividend while XTNT, GKOS, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.